Q32 Bio Inc. (QTTB)
| Market Cap | 83.68M |
| Revenue (ttm) | 53.74M |
| Net Income (ttm) | 29.82M |
| Shares Out | 14.63M |
| EPS (ttm) | 2.42 |
| PE Ratio | 2.36 |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 166,988 |
| Open | 5.39 |
| Previous Close | 5.47 |
| Day's Range | 5.36 - 5.85 |
| 52-Week Range | 1.35 - 8.05 |
| Beta | -1.02 |
| Analysts | Strong Buy |
| Price Target | 13.00 (+127.27%) |
| Earnings Date | May 14, 2026 |
About QTTB
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human anti–interleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatm... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to one analyst, the rating for QTTB stock is "Strong Buy" and the 12-month stock price target is $13.0.
News
Q32 Bio Transcript: 25th Annual Needham Virtual Healthcare Conference
Bempikibart, a bifunctional antibody for alopecia areata, is in phase II with mid-year data expected. The drug targets key immune pathways and aims to address significant unmet needs with a differentiated safety and administration profile. Cash runway extends through Q4 2027.
Q32 Bio to Participate in the 25th Annual Needham Virtual Healthcare Conference
WALTHAM, Mass., April 8, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Q32 Bio Reports Fourth Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; 36-week topline data readout expected in mid-2026 -- -- Complete...
Q32 Bio Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference
Bempikibart is advancing in alopecia areata with promising proof-of-concept and a robust phase IIa program, aiming to address unmet needs with a safer, durable biologic. Top-line 36-week data are expected midyear, with a focus on expanding into other T-cell driven diseases.
Q32 Bio to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference
WALTHAM, Mass., Feb. 18, 2026 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Q32 Bio Announces $10.5 Million Registered Direct Offering
WALTHAM, Mass., Feb. 17, 2026 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ot...
Dow Dips 200 Points; Q32 Bio Shares Jump
Q32 Bio Inc. (NASDAQ:QTTB) shares shot up 171% to $5.91 after the company sold its Phase 2 complement inhibitor ADX-097 to Akebia for $12 million upfront and potential milestone and royalty payments u...
Why Is Small-Cap Q32 Bio Stock Soaring On Monday?
Q32 Bio Inc. (NASDAQ: QTTB) stock is trading higher on Monday, with a session volume of 70.56 million compared to the average volume of 217.704 thousand as per data from Benzinga Pro.
Q32 Bio Sells Complement Inhibitor ADX-097
-- Asset sale further enables Company's strategic focus on advancing bempikibart for alopecia areata -- -- $12 million in upfront and guaranteed near-term milestone payments expected to extend cash ru...
Q32 Bio Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-- Completed enrollment in Part B of SIGNAL-AA Phase 2a clinical trial and increased trial size to 33 patients based on patient demand; topline data readout expected in mid-2026 -- -- Dosing of patien...
Q32 Bio Announces Completion of Enrollment in Part B of SIGNAL-AA Phase 2a Clinical Trial of Bempikibart for Alopecia Areata
-- SIGNAL-AA Part B exceeded target enrollment based on demand from patients; trial size increased to 33 patients -- WALTHAM, Mass. , Oct. 21, 2025 /PRNewswire/ -- Q32 Bio Inc. (NASDAQ: QTTB) ("Q32 Bi...
Q32 Bio Transcript: Wells Fargo 20th Annual Healthcare Conference 2025
Bempikibart is advancing in phase II-B for alopecia, showing earlier and durable responses with a strong safety profile. Operational changes and a new dosing strategy are improving trial outcomes, and the company is well-funded into 2027.
Q32 Bio to Participate in the 2025 Wells Fargo Healthcare Conference
WALTHAM, Mass. , Aug. 28, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and o...
Q32 Bio Reports Second Quarter 2025 Financial Results and Provides Corporate Update
-- Dosing of patients in Part A open-label extension (OLE) and Part B of SIGNAL-AA ongoing; SIGNAL-AA Part B topline data readout on-track for 1H'26 -- -- Strengthened leadership team with appointment...
Q32 Bio Appoints Adrien Sipos, M.D., Ph.D., as Interim Chief Medical Officer
-- Dr. Sipos is an immunologist and seasoned Immunology and Inflammation (I&I) drug developer, with over 25 years of clinical development and medical affairs leadership experience -- WALTHAM, Mass. , ...
Q32 Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update
-- First patient dosed in SIGNAL-AA Phase 2a Part B; topline data readout on-track for 1H'26 -- -- First patient dosed in SIGNAL-AA Part A open-label extension (OLE) -- -- Fast Track designation (FTD)...
Q32 Bio Announces FDA Fast Track Designation Granted to Bempikibart (ADX-914) for the Treatment of Alopecia Areata
WALTHAM, Mass. , April 30, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing innovative therapies for alopecia areata (AA) and ...
Q32 Bio Doses First Patients in Both Part A Open-Label Extension and Part B of SIGNAL-AA Phase 2a Trial Evaluating Bempikibart in Alopecia Areata
-- SIGNAL-AA Part B topline data readout on-track for 1H'26 -- WALTHAM, Mass. , April 16, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio" or the "Company"), a clinical stage biotechnology ...
Q32 Bio Transcript: Leerink Global Healthcare Conference 2025
Bempikibart is now the clinical focus, showing durable hair regrowth in alopecia areata and a strong safety and biomarker profile. An adaptive Part B trial will optimize dosing for phase III, while broader autoimmune indications and strategic options for the Complement Program are being explored.
Q32 Bio Reports Fourth Quarter 2024 Financial Results and Provides Corporate Update
-- Presented bempikibart SIGNAL-AA Phase 2a Part A alopecia areata (AA) data demonstrating encouraging clinical activity and highlighting the potential to be a differentiated treatment as a late-break...
Q32 Bio Presents Results from SIGNAL-AA Part A Clinical Trial Evaluating Bempikibart in Patients with Alopecia Areata at the 2025 American Academy of Dermatology Meeting
-- Results presented in AAD late-breaker demonstrate bempikibart's encouraging improvement on SALT reduction at week 24 and continued effects after dosing cessation in patients with severe and very se...
Q32 Bio Transcript: TD Cowen 45th Annual Healthcare Conference
Bempikibart shows durable, long-term hair regrowth in severe alopecia areata, with a strong safety profile and potential to become the first biologic frontline therapy in a large, underserved market. Expansion into other immune diseases is supported by robust biomarker data.
Q32 Bio Announces Late-Breaking Presentation of Results from SIGNAL-AA Part A Clinical Trial of Bempikibart in Alopecia Areata at the 2025 American Academy of Dermatology Annual Meeting
-- Oral presentation to highlight Phase 2a Part A results of the randomized, placebo-controlled SIGNAL-AA clinical trial evaluating bempikibart in patients with severe and very severe alopecia areata ...
Q32 Bio to Participate in Upcoming March Investor Conferences
WALTHAM, Mass. , Feb. 26, 2025 /PRNewswire/ -- Q32 Bio Inc. (Nasdaq: QTTB) ("Q32 Bio"), a clinical stage biotechnology company focused on developing biologic therapeutics to restore immune homeostasis...
Q32 Bio Transcript: Oppenheimer 35th Annual Healthcare Life Sciences Conference (Virtual) 2025
Bempikibart demonstrated durable, remissive hair regrowth in severe alopecia areata, with effects persisting well after treatment cessation and a strong safety profile. The company is prioritizing this asset, launching new trials, and targeting a large, underserved market with no current biologic competitors.